Idelalisib Tablet, Film Coated
NDC Package 63285-754-01
Package Information
Idelalisib tablets is a medication used to treat certain types of cancer (such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin's lymphoma, small lymphocytic lymphoma-SLL). This formulation utilizes a tablet, film coated delivery system. Marketed by Patheon Inc., this product is identified by NDC 63285-754.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63285 - Patheon Inc.
- 63285-754 -
- 63285-754-01 - 80 BOTTLE in 1 CONTAINER / 60 TABLET, FILM COATED in 1 BOTTLE
- 63285-754 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63285-754-01 identifies a specific commercial package of 80 bottle in 1 container / 60 tablet, film coated in 1 bottle of Idelalisib (UNFINISHED drug), drug for further processing labeled by Patheon Inc.. This tablet, film coated is formulated for use and contains idelalisib as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Patheon Inc. on July 23, 2014. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of cancer (such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin's lymphoma, small lymphocytic lymphoma-SLL). Idelalisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
How is this Patheon Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63285075401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.